The epigenetic drug development landscape has been dominated by two approved drug classes: DNMT inhibitors (azacitidine, decitabine) and HDAC inhibitors (vorinostat, romidepsin, belinostat, panobinostat). Despite years of clinical investigation, no new epigenetic target class has produced an approved therapy. That may be about to change with pelabresib (CPI-0610), a BET bromodomain inhibitor that has reached Phase 3 clinical trials for myelofibrosis.
Pelabresib’s advancement represents a milestone not just for myelofibrosis treatment but for the entire epigenetic drug field. If approved, it would validate BET bromodomain inhibition as a viable therapeutic strategy after more than a decade of clinical development marked by both promise and disappointment across multiple BET inhibitor programs.
Understanding BET Bromodomain Biology
The BET (Bromodomain and Extra-Terminal domain) family consists of four proteins: BRD2, BRD3, BRD4, and BRDT. These proteins function as epigenetic readers, recognizing and binding to acetylated lysine residues on histones. By reading these epigenetic marks, BET proteins recruit transcriptional machinery to gene promoters and enhancers, driving the expression of genes involved in cell growth, differentiation, and inflammation.
BRD4 is the most studied family member and has been implicated in maintaining the expression of oncogenes including MYC, a transcription factor that drives proliferation in many cancer types. The rationale for BET inhibition in cancer is straightforward: by blocking BRD4’s ability to read acetylated histones, you can suppress the transcriptional programs that sustain malignant growth.
In myelofibrosis specifically, BET proteins play a role in maintaining the inflammatory cytokine milieu and abnormal megakaryocyte biology that characterize the disease. Myelofibrosis involves progressive bone marrow fibrosis, abnormal blood cell production, and debilitating symptoms including fatigue, night sweats, and splenomegaly. Current treatment with JAK inhibitors (ruxolitinib, fedratinib, pacritinib) provides symptom relief but does not fundamentally alter disease biology in most patients.
Pelabresib’s Clinical Journey
Pelabresib reached Phase 3 based on Phase 2 data showing that the combination of pelabresib with ruxolitinib produced spleen volume reductions and symptom improvements superior to ruxolitinib alone in myelofibrosis patients. The combination also showed encouraging signals in reducing bone marrow fibrosis, suggesting a potential disease-modifying effect that JAK inhibitors alone have not consistently demonstrated.
The rationale for combining a BET inhibitor with a JAK inhibitor is mechanistically compelling. JAK inhibitors address the JAK-STAT signaling axis that drives many myelofibrosis symptoms. BET inhibition addresses the broader transcriptional dysregulation, including NF-kB-driven inflammatory gene expression and abnormal megakaryocyte differentiation programs. Together, the two mechanisms provide complementary coverage of the disease’s molecular drivers.
The BET Inhibitor Tool Compound Landscape
The development of BET inhibitors has generated a rich set of tool compounds that are widely used in epigenetic research. The first breakthrough compound was (+)-JQ-1, developed in the Bradner laboratory, which demonstrated that BET bromodomain inhibition was technically feasible and biologically active. JQ-1 remains one of the most commonly used BET inhibitor tool compounds in academic research.
Immunomart carries several BET-related research compounds. (+)-JQ-1 is available as a research standard for cell-based and biochemical studies of BET biology. I-BET151, developed by GlaxoSmithKline, offers a structurally distinct BET inhibitor scaffold useful for orthogonal validation of BET-dependent phenotypes. BRD4 degrader-5 enables degradation-based approaches that eliminate BRD4 protein entirely, allowing researchers to distinguish between the catalytic and scaffolding functions of BRD4.
For researchers interested in the intersection of BET biology and other epigenetic mechanisms, DNMT1/HDAC-IN-1 represents the dual-target inhibitor approach, while PFI-2, a SETD7 methyltransferase inhibitor, and UNC0638 hydrate, a G9a/GLP methyltransferase inhibitor, provide tools for studying histone methylation – another key epigenetic regulatory mechanism that intersects with BET-dependent transcription.
Myelofibrosis Research: Beyond JAK Inhibition
The pelabresib program reflects a broader recognition that myelofibrosis biology involves multiple dysregulated pathways. Several JAK inhibitors are already available for research and clinical use. Pacritinib hydrochloride and Pacritinib citrate (both salt forms are available from Immunomart) target JAK2 and FLT3, while Momelotinib HCl inhibits JAK1, JAK2, and ACVR1. Bomedemstat and Bomedemstat ditosylate, LSD1 inhibitors also in myelofibrosis trials, represent yet another epigenetic approach to the disease.
For research laboratories studying myelofibrosis biology, having access to compounds targeting different pathway nodes enables the systematic investigation of pathway interactions. Which combinations show synergy in reducing inflammatory cytokine production? Does BET inhibition sensitize JAK inhibitor-resistant cells? How does the order and timing of pathway blockade affect outcomes? These are the questions driving current translational research, and answering them requires diverse, well-characterized tool compound panels.
The Ziftomenib Precedent
Pelabresib is not the only epigenetic program generating excitement. Ziftomenib, a selective menin-KMT2A interaction inhibitor, received FDA Breakthrough Therapy designation in 2024 for relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Together with pelabresib, these programs suggest that the next wave of approved epigenetic therapies may target the reader proteins and protein-protein interactions that translate epigenetic marks into transcriptional output, rather than the enzymes that write or erase those marks.
For the epigenetic drug development field, the message is encouraging: persistence in clinical development, combined with improved patient selection and rational combination strategies, can overcome the challenges that have slowed earlier epigenetic programs. The market for HDAC inhibitors alone is projected to exceed $160 million in 2026, and the addition of BET inhibitors and other epigenetic modulators could significantly expand the therapeutic landscape.
What Researchers Should Watch
The pelabresib Phase 3 readout will be one of the most closely watched data events in epigenetic drug development. If positive, it would validate BET inhibition as a clinically meaningful mechanism and likely stimulate renewed investment in BET-targeted programs across oncology and potentially autoimmune diseases. For researchers working with BET inhibitors and epigenetic modulators in the laboratory, the clinical validation of these targets adds translational relevance to fundamental mechanistic studies.
Research Use Only Disclaimer: All small molecule inhibitors and research compounds mentioned in this article are intended for laboratory research use only (RUO). They are not approved for human or veterinary use, not intended for diagnostic or therapeutic purposes, and must not be used as drugs, food additives, or household chemicals. Always follow your institution’s safety protocols when handling research compounds.
